AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27860037 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centred communication with need-orientation (PCC-N)
Number of subjects: 80
Study 25850462 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic blood pressure target (<130 mmHg)
Number of subjects: 494
Study 25850462 — intervention group
Group type: COMPARATOR
Intervention: Higher systolic blood pressure target (130-149 mmHg)
Number of subjects: 494
Study 25000912 — intervention group
Group type: EXPERIMENTAL
Intervention: TAU+CAT
Number of subjects: 30
Study 25000912 — intervention group
Group type: COMPARATOR
Intervention: TAU
Number of subjects: 30
Study 22304885 — intervention group
Group type: EXPERIMENTAL
Intervention: Disgust induction (view vomit videos)
Number of subjects: 0
Study 22304885 — intervention group
Group type: COMPARATOR
Intervention: Neutral activation (view waterfall videos)
Number of subjects: 0
Study 19875482 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 2 mg/d subcutaneously for 8 weeks
Number of subjects: 17
Study 19875482 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH)
Number of subjects: 17
Study 17201013 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound group (n=21)
Number of subjects: 41
Study 17201013 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 41
Study 15198378 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced (digital) hearing aids
Number of subjects: 100
Study 11171825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 10%
Number of subjects: 10
Study 11171825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 20%
Number of subjects: 10
Study 11171825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 30%
Number of subjects: 10
Study 11171825 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine gel 40%
Number of subjects: 10
Study 11171825 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0%)
Number of subjects: 10
Study 9867272 — intervention group
Group type: EXPERIMENTAL
Intervention: Unenhanced CT following oral contrast medium
Number of subjects: 118
Study 9867272 — intervention group
Group type: COMPARATOR
Intervention: Barium enema (BE)
Number of subjects: 118
Study 8561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Control interventions implemented in Mindjil village
Number of subjects: 0
Study 8561256 — intervention group
Group type: COMPARATOR
Intervention: Control interventions not implemented (excluded areas)
Number of subjects: 0
Study 2702970 — intervention group
Group type: EXPERIMENTAL
Intervention: pindolol 15 mg bd + digoxin
Number of subjects: 12
Study 2702970 — intervention group
Group type: COMPARATOR
Intervention: digoxin + verapamil 40 mg tds
Number of subjects: 12
Study 347034 — intervention group
Group type: EXPERIMENTAL
Intervention: polyinosinic-polycytidylic acid (rIn.rCn) at doses of 9 and 12 mg/kg (Lot 1)
Number of subjects: 31
Study 347034 — intervention group
Group type: EXPERIMENTAL
Intervention: polyinosinic-polycytidylic acid (rIn.rCn) at doses of 3-12 mg/kg (Lot 2)
Number of subjects: 31
Study 347034 — intervention group
Group type: EXPERIMENTAL
Intervention: polyinosinic-polycytidylic acid (rIn.rCn)
Number of subjects: 31
Study 347034 — intervention group
Group type: COMPARATOR
Intervention: Control group (7 patients with herpes zoster)
Number of subjects: 31
Study 30577404 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery
Number of subjects: 2228
Study 30577404 — intervention group
Group type: COMPARATOR
Intervention: Initial radiation therapy
Number of subjects: 2228
Study 28895981 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar RFT (80°C) for 2 minutes at L2‐3 level
Number of subjects: 30
Study 28895981 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar RFT (80°C) for 2 minutes at L2‐3 level
Number of subjects: 30
Study 28895981 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 25894666 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group intervention
Number of subjects: 378
Study 25894666 — intervention group
Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 378
Study 25894666 — intervention group
Group type: COMPARATOR
Intervention: Brochure control
Number of subjects: 378
Study 24114738 — intervention group
Group type: EXPERIMENTAL
Intervention: Different opportunity costs of the rare disease
Number of subjects: 0
Study 24114738 — intervention group
Group type: EXPERIMENTAL
Intervention: Different framings of the trade‐off exercises
Number of subjects: 0
Study 21871372 — intervention group
Group type: EXPERIMENTAL
Intervention: OROS‐MPH + CBT
Number of subjects: 303
Study 21871372 — intervention group
Group type: COMPARATOR
Intervention: Placebo + CBT
Number of subjects: 303
Study 19152543 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonality-focused contact
Number of subjects: 0
Study 19152543 — intervention group
Group type: COMPARATOR
Intervention: Difference-focused contact
Number of subjects: 0
Study 19152543 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive intergroup contact
Number of subjects: 0
Study 17497438 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus Oral Hygiene Program (OHP)
Number of subjects: 20
Study 17497438 — intervention group
Group type: COMPARATOR
Intervention: Oral Hygiene Program (OHP) alone
Number of subjects: 20
Study 14767720 — intervention group
Group type: EXPERIMENTAL
Intervention: Entacapone (200 mg)
Number of subjects: 12
Study 14767720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11491148 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg ciclesonide in the morning
Number of subjects: 209
Study 11491148 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg ciclesonide in the evening
Number of subjects: 209
Study 11491148 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg ciclesonide (morning or evening)
Number of subjects: 209
Study 9926056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive community service
Number of subjects: 124
Study 9926056 — intervention group
Group type: COMPARATOR
Intervention: Standard service
Number of subjects: 124
Study 9926056 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall care-giving activities
Number of subjects: 124
Study 9926056 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall dissatisfaction with care-giving role
Number of subjects: 124
Study 9926056 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and illness characteristics
Number of subjects: 124
Study 9100253 — intervention group
Group type: EXPERIMENTAL
Intervention: Odorant air containing amyl acetate or phenethyl alcohol
Number of subjects: 14
Study 9100253 — intervention group
Group type: COMPARATOR
Intervention: Odorless air
Number of subjects: 14
Study 1743245 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrazepam 5 mg/d
Number of subjects: 28
Study 1743245 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxazepam 25 mg/d
Number of subjects: 28
Study 1743245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7261554 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (alkalosis)
Number of subjects: 5
Study 7261554 — intervention group
Group type: EXPERIMENTAL
Intervention: NH4Cl (acidosis)
Number of subjects: 5
Study 7261554 — intervention group
Group type: COMPARATOR
Intervention: CaCO3 (control)
Number of subjects: 5
Study 31467115 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled α1-antitrypsin (AAT) 80 mg solution, twice daily for 50 weeks
Number of subjects: 168
Study 31467115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 31467115 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled α1-antitrypsin (AAT)
Number of subjects: 168
Study 28052163 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory training program
Number of subjects: 918
Study 28052163 — intervention group
Group type: COMPARATOR
Intervention: Control group 1 (traditional didactic training)
Number of subjects: 918
Study 28052163 — intervention group
Group type: COMPARATOR
Intervention: Control group 2 (traditional didactic training)
Number of subjects: 918
Study 25403774 — intervention group
Group type: EXPERIMENTAL
Intervention: HeartNetCare -HF™ (HNC)
Number of subjects: 0
Study 25403774 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study 24639423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite (70 μmol) administered over 5 min immediately before primary percutaneous intervention (PPCI)
Number of subjects: 229
Study 24639423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching infusion)
Number of subjects: 229
Study 24639423 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium nitrite
Number of subjects: 229
Study 24639423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 22695223 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential processing mode during anticipatory processing
Number of subjects: 168
Study 22695223 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiential processing mode during post-event rumination
Number of subjects: 168
Study 22695223 — intervention group
Group type: COMPARATOR
Intervention: Analytical processing mode during anticipatory processing
Number of subjects: 168
Study 22695223 — intervention group
Group type: COMPARATOR
Intervention: Analytical processing mode during post-event rumination
Number of subjects: 168
Study 20206784 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐AmB 5 mg/kg per week
Number of subjects: 40
Study 20206784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrose water)
Number of subjects: 40
Study 18339112 — intervention group
Group type: EXPERIMENTAL
Intervention: Single tailored intervention (one tailored letter)
Number of subjects: 508
Study 18339112 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple tailored intervention (three tailored letters at intervals of 1 month)
Number of subjects: 508
Study 18339112 — intervention group
Group type: COMPARATOR
Intervention: General practitioner letter (control)
Number of subjects: 508
Study 15982116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminating for 25 min
Number of subjects: 3
Study 15982116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminating for 8-hr
Number of subjects: 3
Study 15982116 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruminating
Number of subjects: 3
Study 15982116 — intervention group
Group type: COMPARATOR
Intervention: Distracted participants
Number of subjects: 3
Study 12839661 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention including health education for smoking cessation, alcohol consumption restriction, and reinforced treatment for diabetic and hypertensive patients.
Number of subjects: 5309
Study 12839661 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no intervention).
Number of subjects: 5309
Study 12839661 — intervention group
Group type: EXPERIMENTAL
Intervention: Community intervention.
Number of subjects: 5309
Study 10489946 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmyocardial revascularisation (TMR)
Number of subjects: 182
Study 10489946 — intervention group
Group type: COMPARATOR
Intervention: Continued medication
Number of subjects: 182
Study 9374151 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral thoracodorsal flap (LTD)
Number of subjects: 56
Study 9374151 — intervention group
Group type: EXPERIMENTAL
Intervention: Latissimus dorsi flap (LD)
Number of subjects: 56
Study 9374151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled transverse rectus abdominis musculocutaneous (TRAM) flap
Number of subjects: 56
Study 9374151 — intervention group
Group type: COMPARATOR
Intervention: Irradiated patients (LD and TRAM)
Number of subjects: 56
Study 1329476 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 0
Study 1329476 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0
Study 1329476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Lisinopril and Nitrates
Number of subjects: 0
Study 1329476 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 2414253 — intervention group
Group type: EXPERIMENTAL
Intervention: Bleomycin injected intramuscularly 1 hour before radiation treatment daily for 5 days a week
Number of subjects: 222
Study 2414253 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy without added chemotherapy
Number of subjects: 222
Study 30859872 — intervention group
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS program
Number of subjects: 10
Study 30859872 — intervention group
Group type: COMPARATOR
Intervention: Non-TeamSTEPPS group
Number of subjects: 10
Study 29438370 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobimetinib plus vemurafenib (C+V)
Number of subjects: 0
Study 29438370 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus vemurafenib (P+V)
Number of subjects: 0
Study 25789594 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin and trace element composition
Number of subjects: 159
Study 25789594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 24064933 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 69
Study 24064933 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam
Number of subjects: 69
Study 24064933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 21960653 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) sessions (4 sessions, 30-45 minutes each) plus usual care
Number of subjects: 146
Study 21960653 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual care
Number of subjects: 146
Study 19237438 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-bonded catheters
Number of subjects: 87
Study 19237438 — intervention group
Group type: COMPARATOR
Intervention: Standard non-heparin-bonded catheters
Number of subjects: 87
Study 17324206 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyquad-based care regimen
Number of subjects: 41
Study 17324206 — intervention group
Group type: COMPARATOR
Intervention: PHMB-based care regimen
Number of subjects: 41
Study 17324206 — intervention group
Group type: EXPERIMENTAL
Intervention: Lotrafilcon A lenses
Number of subjects: 41
Study 17324206 — intervention group
Group type: COMPARATOR
Intervention: Galyfilcon A lenses
Number of subjects: 41
Study 15161390 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional blink induced by RSVP task
Number of subjects: 0
Study 15161390 — intervention group
Group type: COMPARATOR
Intervention: Spatial cues in visual search display
Number of subjects: 0
Study 11301617 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment that halves the risk of new vertebral deformities
Number of subjects: 0
Study 11301617 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 8342264 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific instructions for the early return of gastrointestinal motility (suggestion group)
Number of subjects: 0
Study 8342264 — intervention group
Group type: COMPARATOR
Intervention: Reassurance and nonspecific instructions (control group)
Number of subjects: 0
Study 3534202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating air mattress (14 to 16 regular pulses per minute)
Number of subjects: 122
Study 3534202 — intervention group
Group type: COMPARATOR
Intervention: Conventional mattress
Number of subjects: 122
Study 3534202 — intervention group
Group type: EXPERIMENTAL
Intervention: Oscillating air mattress
Number of subjects: 122
Study 29729957 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-SR 4/1000 mg once-daily
Number of subjects: 168
Study 29729957 — intervention group
Group type: COMPARATOR
Intervention: GM-IR 2/500 mg BID
Number of subjects: 168
Study 27025241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose C (10 mg mane and 5 mg tarde)
Number of subjects: 10
Study 27025241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose B (10 mg mane and 10 mg tarde)
Number of subjects: 10
Study 27025241 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose A (20 mg mane and 10 mg tarde)
Number of subjects: 10
Study 25647441 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief, structured, telephone tobacco cessation counseling (BST) delivered by clinical pharmacists.
Number of subjects: 120
Study 25647441 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control) provided by clinical pharmacists.
Number of subjects: 120
Study 23192454 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536
Number of subjects: 45
Study 23192454 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 21364772 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (DA) therapy
Number of subjects: 0
Study 21364772 — intervention group
Group type: COMPARATOR
Intervention: No DA therapy (off DA therapy)
Number of subjects: 0
Study 19343887 — intervention group
Group type: EXPERIMENTAL
Intervention: OXY‐TDS (transdermal oxybutynin)
Number of subjects: 699
Study 17217715 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD2 group (30 patients)
Number of subjects: 130
Study 17217715 — intervention group
Group type: EXPERIMENTAL
Intervention: CHD3 group (30 patients)
Number of subjects: 130
Study 17217715 — intervention group
Group type: COMPARATOR
Intervention: non-CHD group (39 patients)
Number of subjects: 130
Study 17217715 — intervention group
Group type: COMPARATOR
Intervention: CHD1 group (30 patients)
Number of subjects: 130
Study 17217715 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive rHR (or HRR) without ST lowering during exercise
Number of subjects: 130
Study 17217715 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Duke score
Number of subjects: 130
Study 17217715 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation with Gensini score
Number of subjects: 130
Study 12861415 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resistance/high-repetition knee extension exercise in normobaric hypoxia (FiO2 0.12)
Number of subjects: 19
Study 12861415 — intervention group
Group type: COMPARATOR
Intervention: Low-resistance/high-repetition knee extension exercise in normoxia
Number of subjects: 19
Study 10871974 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 or 30 mg once daily
Number of subjects: 901
Study 10871974 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 901
Study 10871974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 901
Study 9105542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliquidone 30 mg tablet administered 15 min before breakfast
Number of subjects: 32
Study 1583434 — intervention group
Group type: EXPERIMENTAL
Intervention: Dinamap 1846SX
Number of subjects: 293
Study 1583434 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random zero sphygmomanometer
Number of subjects: 293
Study 3327018 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing close to total lung capacity (TLC)
Number of subjects: 5
Study 3327018 — intervention group
Group type: COMPARATOR
Intervention: Breathing close to residual volume (RV)
Number of subjects: 5
Study 31944821 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone beam CT (CBCT) imaging to measure the radiolucency area around the crown of impacted maxillary canines.
Number of subjects: 58
Study 29480324 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG-concentrated green tea extract (GTE) low dose
Number of subjects: 13
Study 29480324 — intervention group
Group type: EXPERIMENTAL
Intervention: EGCG-concentrated green tea extract (GTE) high dose
Number of subjects: 13
Study 29480324 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 13
Study 27144300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with fixed pulse amplitude for 40 minutes (Group A)
Number of subjects: 45
Study 27144300 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation with adjusted pulse amplitude for 40 minutes (Group B)
Number of subjects: 45
Study 27144300 — intervention group
Group type: COMPARATOR
Intervention: Exercises only (Group C)
Number of subjects: 45
Study 25601635 — intervention group
Group type: EXPERIMENTAL
Intervention: GSD-SZ+TAU
Number of subjects: 101
Study 25601635 — intervention group
Group type: COMPARATOR
Intervention: TAU alone
Number of subjects: 101
Study 23843474 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofortified pearl millet
Number of subjects: 40
Study 23843474 — intervention group
Group type: COMPARATOR
Intervention: Control (non-biofortified pearl millet)
Number of subjects: 40
Study 20969457 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 71
Study 20969457 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 19694878 — intervention group
Group type: EXPERIMENTAL
Intervention: Transparent disc application (intervention group)
Number of subjects: 9762
Study 19694878 — intervention group
Group type: COMPARATOR
Intervention: Finger method (control group)
Number of subjects: 9762
Study 16505520 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral group
Number of subjects: 54
Study 16505520 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral group
Number of subjects: 54
Study 15628112 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacologically treated APE patients
Number of subjects: 36
Study 15628112 — intervention group
Group type: COMPARATOR
Intervention: Age-matched controls (30 subjects, 12 men, 18 women, age 67 ± 12 years)
Number of subjects: 36
Study 11348882 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/d)
Number of subjects: 19
Study 11348882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Atorvastatin and bile acid sequestrant)
Number of subjects: 19
Study 11348882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 9009924 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous lip bumper therapy for 6 months
Number of subjects: 34
Study 9009924 — intervention group
Group type: COMPARATOR
Intervention: Nontreatment (control group) for 6 months
Number of subjects: 34
Study 8392282 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg
Number of subjects: 72
Study 8392282 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril 2.5 mg
Number of subjects: 72